<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[company and pharmaceutical company Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/company+and+pharmaceutical+company.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to company and pharmaceutical company]]></description>
	<s:counts start="0" returned="20" found="63" />
	<language>en-us</language>
	<item>
		<title><![CDATA[SILENCE THERAPEUTICS PLC - Preliminary Final Results.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200803/ai_n25298071]]></link>
		<description><![CDATA[SILENCE THERAPEUTICS PLC           ("Silence Therapeutics", "Silence", "the Group" or "the Company")                PRELIMINARY UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS         ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 27 Mar 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/astrazeneca+plc..html"><![CDATA[AstraZeneca Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/collaboration.html"><![CDATA[collaboration]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/molecule.html"><![CDATA[molecule]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/technology.html"><![CDATA[technology]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
		<category domain="tickers">AZN</category>
	</item>
	<item>
		<title><![CDATA[Arrowhead Streamlines Business Model of Nanobiotech Subs, Calando Pharmaceuticals and Insert Therapeutics]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Feb_28/ai_n24354121]]></link>
		<description><![CDATA[PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR) announced today a fundamental streamlining of its majority-owned subsidiaries, Calando Pharmaceuticals and Insert Therapeutics. Arrowhead will assume active management of the companies and focus resources on bringing multiple products to the clinic as rapidly as possible. Arrowhead's expanded role is intended to make...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 28 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[APP Pharmaceuticals Receives Letter Regarding Nasdaq Rule 4350]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Dec_18/ai_n27478644]]></link>
		<description><![CDATA[SCHAUMBURG, Ill. -- APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading manufacturer of multi-source and branded injectable pharmaceutical products, today said it received a letter from The Nasdaq Stock Market, Inc. indicating that the Company was no longer in compliance with Nasdaq's Marketplace Rule 4350d(2). This rule requires the Company to have...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 18 Dec 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/audit.html"><![CDATA[audit]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Axcan Pharma to Present at the Credit Suisse Annual Healthcare Conference.(Conference news)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200711/ai_n22575086]]></link>
		<description><![CDATA[MONT-SAINT-HILAIRE, QUEBEC, Nov 7, 2007 Marketwire via COMTEX --  Axcan Pharma Inc. ("Axcan" or the "Company")  (TSX:AXP)(NASDAQ:AXCA) today announced that on Tuesday, November 13,  2007, Senior Vice President and Chief Financial O  MONT-SAINT-HILAIRE, QUEBEC, Nov 7, 2007 Marketwire via COMTEX --  Axcan Pharma Inc. ("Axcan"...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 07 Nov 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/credit+suisse+group+ag.html"><![CDATA[Credit Suisse Group AG]]></category>
	</item>
	<item>
		<title><![CDATA[Axcan Pharma to Present at the UBS Global Life Sciences Conference.(Conference news)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200709/ai_n22568958]]></link>
		<description><![CDATA[MONT-SAINT-HILAIRE, QUEBEC, Sep 19, 2007 CCNMatthews via COMTEX  -- Axcan Pharma Inc. ("Axcan" or the "Company")  (TSX:AXP)(NASDAQ:AXCA) today announced that on Wednesday, September 26,  2007, President and Chief Executive Officer,  MONT-SAINT-HILAIRE, QUEBEC, Sep 19, 2007 CCNMatthews via COMTEX  -- Axcan Pharma Inc. ("Axcan" or the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 19 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/life+science.html"><![CDATA[life science]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/ubs+ag.html"><![CDATA[UBS AG]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">UBS</category>
		<category domain="tickers">UBS</category>
	</item>
	<item>
		<title><![CDATA[Axcan Pharma to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in London, UK.(Conference news)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200709/ai_n22568349]]></link>
		<description><![CDATA[MONT-SAINT-HILAIRE, QUEBEC, Sep 14, 2007 CCNMatthews via COMTEX  -- Axcan Pharma Inc. ("Axcan" or the "Company")  (TSX:AXP)(NASDAQ:AXCA) today announced that on Tuesday, September 18,  2007, President and Chief Executive Officer, F  MONT-SAINT-HILAIRE, QUEBEC, Sep 14, 2007 CCNMatthews via COMTEX  -- Axcan Pharma Inc. ("Axcan" or...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 14 Sep 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/merrill+lynch+%2526+co.+inc..html"><![CDATA[Merrill Lynch & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MER</category>
		<category domain="tickers">MER</category>
	</item>
	<item>
		<title><![CDATA[Drugmaker ready for outbreak.(Spotlight: RIMS 2007 Trends & Developments)(F. Hoffmann-La Roche Ltd. preparations for a deadly pandemic)(Brief article)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5252/is_200705/ai_n20165210]]></link>
		<description><![CDATA[Byline: Gloria Gonzalez    Being the manufacturer of the No. 1 prescribed influenza medication  has put pharmaceutical company F. Hoffmann-La Roche Ltd. at the  forefront of preparations for a potentially deadly pandemic.    As part of its pandemic prep  Byline: Gloria Gonzalez ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 14 May 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Axcan Pharma to Present at the UBS Global Generic and Specialty Pharmaceuticals Conference.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200705/ai_n22553481]]></link>
		<description><![CDATA[MONT-SAINT-HILAIRE, QUEBEC, May 2, 2007 CCNMatthews via COMTEX --  Axcan Pharma Inc. ("Axcan" or the "Company")  (TSX:AXP)(NASDAQ:AXCA) today announced that on Tuesday, May 8, 2007,  Senior Vice President and Chief Financial Office  MONT-SAINT-HILAIRE, QUEBEC, May 2, 2007 CCNMatthews via COMTEX --  Axcan Pharma Inc. ("Axcan"...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 02 May 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/ubs+ag.html"><![CDATA[UBS AG]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">UBS</category>
		<category domain="tickers">UBS</category>
	</item>
	<item>
		<title><![CDATA[NOVARTIS' EXPANSION CONTINUES IN CHINA]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5562/is_200703/ai_n22742272]]></link>
		<description><![CDATA[AsiaInfo Services    03-20-2007    Novartis' Expansion Continues in China    BEIJING, Mar 20, 2007 SinoCast via COMTEX -- Novartis AG, the world's fourth-largest pharmaceutical company, plans to invest more in research and development of the Chinese h  AsiaInfo Services   ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 20 Mar 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[company]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">NVS</category>
	</item>
	<item>
		<title><![CDATA[Forbes Medi-Tech Announces Next Steps in Pharmaceutical Development and Corporate Restructuring]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200702/ai_n17219227]]></link>
		<description><![CDATA[Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) today announced the next steps for its pharmaceutical development program and restructuring measures in R&D to extend the Company's working capital and optimize the Company's remaining capital resources. Based on the results from the recently completed US Phase II trial, the Company's immediate pharmaceutical...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 12 Feb 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+restructuring.html"><![CDATA[corporate restructuring]]></category>
		<category domain="http://resources.bnet.com/topic/forbes.html"><![CDATA[Forbes]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Forbes Medi-Tech Announces Next Steps in Pharmaceutical Development and Corporate Restructuring; Company Eliminates Non-Core R&D Expenses and Extends Working Capital to Mid 2008.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200702/ai_n22544506]]></link>
		<description><![CDATA[VANCOUVER, BRITISH COLUMBIA, Feb 12, 2007 CCNMatthews via COMTEX  -- Forbes Medi-Tech Inc. (TSX:FMI)(NASDAQ:FMTI) today announced the next  steps for its pharmaceutical development program and restructuring  measures in R&D to extend the Company's  VANCOUVER, BRITISH COLUMBIA, Feb 12, 2007 CCNMatthews via COMTEX  -- Forbes Medi-Tech...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 12 Feb 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+restructuring.html"><![CDATA[corporate restructuring]]></category>
		<category domain="http://resources.bnet.com/topic/forbes.html"><![CDATA[Forbes]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/r%2526d.html"><![CDATA[R&D]]></category>
		<category domain="http://resources.bnet.com/topic/working+capital.html"><![CDATA[working capital]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Axcan to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology, and Medical Device Conference.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200701/ai_n22542936]]></link>
		<description><![CDATA[MONT-SAINT-HILAIRE, QUEBEC, Jan 31, 2007 CCNMatthews via COMTEX  -- Axcan Pharma Inc. ("Axcan" or the "Company")  (TSX:AXP)(NASDAQ:AXCA) today announced that on Tuesday, February 6,  2007, President and Chief Executive Officer, Fra  MONT-SAINT-HILAIRE, QUEBEC, Jan 31, 2007 CCNMatthews via COMTEX  -- Axcan Pharma Inc. ("Axcan" or...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 31 Jan 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/medical+device.html"><![CDATA[medical device]]></category>
		<category domain="http://resources.bnet.com/topic/merrill+lynch+%2526+co.+inc..html"><![CDATA[Merrill Lynch & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MER</category>
		<category domain="tickers">MER</category>
	</item>
	<item>
		<title><![CDATA[Axcan to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference in London, UK.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5559/is_200609/ai_n22528864]]></link>
		<description><![CDATA[MONT SAINT-HILAIRE, QUEBEC, Sep 18, 2006 CCNMatthews via COMTEX  -- Axcan Pharma Inc. ("Axcan" or the "Company") (TSX  VENTURE:AXP) (Nasdaq:AXCA) today announced that on Thursday, September  21, 2006, President and Chief Executive   MONT SAINT-HILAIRE, QUEBEC, Sep 18, 2006 CCNMatthews via COMTEX  -- Axcan Pharma...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 18 Sep 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/merrill+lynch+%2526+co.+inc..html"><![CDATA[Merrill Lynch & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MER</category>
		<category domain="tickers">MER</category>
	</item>
	<item>
		<title><![CDATA[Tranzyme Pharma Receives Notice of Allowance from USPTO on Patent Protecting Company's Macrocyclic Chemistry Technology]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_July_19/ai_n26930008]]></link>
		<description><![CDATA[RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec -- Tranzyme Pharma, a leading biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of gastrointestinal GI and metabolic disorders, announced today that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office USPTO for its patent application...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 19 Jul 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+patent+and+trademark+office.html"><![CDATA[U.S. Patent and Trademark Office]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist&#153; Approvable Letters; Company Remains Committed To Making Novel Blood-Pool Imaging Agent Available in U.S]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_June_30/ai_n26913733]]></link>
		<description><![CDATA[CAMBRIDGE, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a developer of innovative pharmaceuticals for magnetic resonance imaging MRI which recently announced a definitive agreement to merge with Predix Pharmaceuticals Holdings, Inc., today announced that it has submitted a formal appeal to the U.S. Food and Drug Administration FDA asking the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 30 Jun 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+office.html"><![CDATA[Microsoft Office]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[SR PHARMA PLC - Licence agreement signed.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200603/ai_n23960102]]></link>
		<description><![CDATA[SR Pharma plc announces Licence with Merck & Co.    28 March, 2006 - London - SR Pharma plc ("SR Pharma") is pleased to announce  that Merck & Co., Inc. ("Merck") has signed an agreement to in-license know how        ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 28 Mar 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[DENTSPLY International Inc. Provides Pharmaceutical Business Update]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Feb_8/ai_n26754952]]></link>
		<description><![CDATA[YORK, Pa. -- DENTSPLY International Inc. (NASDAQ:XRAY) today announced that, as a result of its continuing evaluation of the dental injectable anesthetic business, the Company will close its Chicago-based Pharmaceutical Manufacturing facility. The Company plans to sell the facility and to seek third party sources of supply for the dental...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 08 Feb 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[SR PHARMA PLC - Result of Equity Issue.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5937/is_200507/ai_n23957665]]></link>
		<description><![CDATA[SR Pharma announces [pounds sterling]10m of new funding following a successful fundraising with    institutional investors and strategic investor, Introgen Therapeutics Inc.,                          ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 28 Jul 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/equity.html"><![CDATA[equity]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Johnson & Johnson: Well Positioned.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4848/is_200505/ai_n17878399]]></link>
		<description><![CDATA[Byline: Kiplinger Washington Editors       Johnson & Johnson JNJ held a meeting with Wall Street  analysts on Thursday to discuss its pharmaceutical pipeline. It was the  first detailed review of the pipeline in four years, and news of several    ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 27 May 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[company]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[European drug strategy makes Forest stand out; Revenue triples in 5 years; does firm need to turn over leaf to stay green?(News)(Forest Laboratories Inc.)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5254/is_200312/ai_n20233406]]></link>
		<description><![CDATA[Byline: samantha marshall    After five years of dizzying gains, Forest Laboratories Inc. has  become one of the few stars in an industry better known for incremental  growth.    Propelled by its ability to rapidly develop European drugs for the  U.S. m ...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 08 Dec 2003 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[company]]></category>
		<category domain="http://resources.bnet.com/topic/forest+laboratories+inc..html"><![CDATA[Forest Laboratories Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[pharmaceutical company]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[strategy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
		<category domain="tickers">FRX</category>
	</item>
</channel>
</rss>
